ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 395 • 2013 ACR/ARHP Annual Meeting

    Sex Differences In Lean Mass Deficits In Rheumatoid Arthritis

    Joshua Baker1, David I. Daikh2 and Patricia P. Katz3, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Significant differences in adiposity between men and women with RA have been observed (1). Another alteration of body composition, rheumatoid cachexia, characterized by low…
  • Abstract Number: 396 • 2013 ACR/ARHP Annual Meeting

    The Dosage Of Prednisolone Is a Risk Factor For Falls In Rheumatoid Arthritis Patients -The Third Year Results Of The Tomorrow Study-

    Yuko Sugioka1, Tatsuya Koike2, Kenji Mamoto1, Tadashi Okano1, Masahiro Tada1, Kentaro Inui3 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

     Background/Purpose: Population-based studies suggest an association between musculoskeletal problems and an increased risk of falls. Patients with rheumatoid arthritis (RA) who have muscle weakness and…
  • Abstract Number: 397 • 2013 ACR/ARHP Annual Meeting

    Does Elevated Disease Activity Or Medication Use Influence The Bone Density Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?

    Florentien D.O. de Steenwinkel1, Anita C.S. Hokken-Koelega2, Johanna Hazes3 and Radboud J.E.M. Dolhain1, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, 3Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Elevated rheumatoid arthritis disease activity and prednisone use during pregnancy  are both associated with a lower bone mineral density (BMD) of the patients, but…
  • Abstract Number: 398 • 2013 ACR/ARHP Annual Meeting

    Does Elevated Disease Activity Or Medication Use Influence The Body Composition Of The Prepubertal Offspring In Pregnant Women With Rheumatoid Arthritis?

    Florentien D.O. de Steenwinkel1, Radboud J.E.M. Dolhain1, Johanna M.W. Hazes2 and Anita C.S. Hokken-Koelega3, 1Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 2Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands

    Background/Purpose: Elevated rheumatoid arthritis (RA) disease activity during pregnancy is associated with lower birth weight and rapid post-natal growth. Lower birth weight and rapid post-natal…
  • Abstract Number: 399 • 2013 ACR/ARHP Annual Meeting

    Nausea and Vomiting During Pregnancy and Spontaneous Abortion In Women With Rheumatoid Arthritis

    Balambal Bharti1, Diana L. Johnson2 and Christina D. Chambers3, 1Pediatrics, University of California San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Pediatrics, University of California, San Diego, La Jolla, CA

    Background/Purpose: Nausea and Vomiting during Pregnancy (NVP) has been associated with a decreased risk for spontaneous abortion (SAB). However, the Th1/Th2 imbalance that occurs in…
  • Abstract Number: 360 • 2013 ACR/ARHP Annual Meeting

    Visit-To-Visit Variability In Blood Pressure In Patients With Rheumatoid Arthritis (RA) Vs General Population, and Its Impact On Cardiovascular Events and All-Cause Mortality In RA

    Elena Myasoedova1, Cynthia S. Crowson2, Abigail B. Green2, Eric L. Matteson3 and Sherine E. Gabriel4, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Blood pressure (BP) variability has been associated with increased risk of cardiovascular (CV) disease and death in the general population. The impact of BP…
  • Abstract Number: 361 • 2013 ACR/ARHP Annual Meeting

    Risk Of Venous Thromboembolism and Use Of Disease-Modifying Antirheumatic Drugs For Rheumatoid Arthritis

    Seoyoung C. Kim1, Daniel H. Solomon2,3, Jun Liu4, Jessica M. Franklin5, Robert J. Glynn6 and Sebastian Schneeweiss7, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Recent research suggests that rheumatoid arthritis (RA), an autoimmune systemic inflammatory disease, increases the risk of venous thromboembolism (VTE) including pulmonary embolism and deep…
  • Abstract Number: 362 • 2013 ACR/ARHP Annual Meeting

    Management Of Hyperlipidemia In Patients With RA: Results From The Corrona Certain Study

    Dimitrios A. Pappas1, Ani John2, Joel M. Kremer3, George W. Reed4, Tanya Sommers4, Jeffrey D. Greenberg5, Ashwini Shewade2 and Jeffrey R. Curtis6, 1Columbia University, New York, NY, 2Genentech Inc., South San Francisco, CA, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 4CORRONA, Inc., Southborough, MA, 5NYU Hospital for Joint Diseases, New York, NY, 67University of Alabama at Birmingham Division of Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose:  RA is associated with an increased risk for cardiovascular disease (CVD).1 Patients (pts) with RA share similar risk for CVD with non-RA pts who are 10 years older…
  • Abstract Number: 363 • 2013 ACR/ARHP Annual Meeting

    Comparing Myocardial Infarction Risks Associated With Biologics Of Varying Mechanisms Of Action Among Older RA Patients

    Jeffrey R. Curtis1, Huifeng Yun2, Jie Zhang3, Fenglong Xie4, Lang Chen5, Emily Levitan2, James Lewis6, Timothy Beukelman7, Kenneth G. Saag8 and Iris Navarro-Millan5, 1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 2Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Medicine, University of Pennsylvania, Philadelphia, PA, 7Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:  Anti-TNF biologics have been associated with a reduced risk for acute myocardial infarction (AMI) in some rheumatoid arthritis (RA) populations. The comparative risks for…
  • Abstract Number: 364 • 2013 ACR/ARHP Annual Meeting

    Hyperuricemia As a Risk Factor for Cardiovascular Disease in Patients With Rheumatoid Arthritis

    Daniel Kuo1, Cynthia S. Crowson2, Sherine E. Gabriel3 and Eric L. Matteson4, 1Mayo Medical School, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular disease (CVD). There is growing evidence that serum uric acid plays an important…
  • Abstract Number: 365 • 2013 ACR/ARHP Annual Meeting

    Oral Calcium Supplementation Is Associated With Subclinical Atherosclerosis In Rheumatoid Arthritis

    Shanthi Dhaduvai1, Laura Geraldino-Pardilla2, Jon T. Giles3 and Joan M. Bathon4, 1Division of Rheumatology, Columbia University Medical Center, New York, NY, 2Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 3Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 4Columbia University, New York, NY

    Background/Purpose: Recent studies in the general population highlight possible adverse cardiovascular effects with calcium supplementation; however, the association between calcium intake and subclinical markers of…
  • Abstract Number: 366 • 2013 ACR/ARHP Annual Meeting

    Traditional Cardiac Risk Factors Predict Significant Coronary Plaque Burden In Asymptomatic Patients With Rheumatoid Arthritis

    George A. Karpouzas1, Jennifer Malpeso2, Tae-Young Choi2, Youngju Pak3 and Matthew Budoff2, 1Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 2Cardiology, Harbor-UCLA Medical Center, Torrance, CA, 3Biostatistics, Harbor-UCLA Medical Center, Torrance, CA

    Background/Purpose: Computed tomography angiography (CTA) provides prognostic information in patients with suspected but unknown coronary artery disease (CAD); subjects without plaque had no incident major…
  • Abstract Number: 367 • 2013 ACR/ARHP Annual Meeting

    Cytomegalovirus-Related Immunity Correlates With Myocardial Disease In Rheumatoid Arthritis

    John M. Davis III1, Cynthia S. Crowson2, Michael A. Strausbauch3, Terry M. Therneau2, Eric L. Matteson1, Keith L. Knutson3 and Sherine E. Gabriel4, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 3Immunology, Mayo Clinic, Rochester, MN, 4Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: We recently discovered correlations between a profile of cytokines produced in response to human cytomegalovirus (CMV), poor treatment outcome, and erosive joint damage. The…
  • Abstract Number: 368 • 2013 ACR/ARHP Annual Meeting

    Detrimental Impact Of Long-Term Cumulative Burden Of Rheumatoid Arthritis (RA) Disease Severity On Cardiovascular Outcomes In RA

    Elena Myasoedova1, Birkan Ilhan2, Helen Khun3, Eric L. Matteson4 and Cynthia S. Crowson3, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Several studies have shown the associations of various measures of rheumatoid arthritis (RA) disease severity with unfavorable cardiovascular (CV) outcomes in RA. The association…
  • Abstract Number: 369 • 2013 ACR/ARHP Annual Meeting

    Prolongation Of QT Interval In Patients With Rheumatoid Arthritis and Its Impact On Mortality: Results From a Population-Based Study

    Krati Chauhan1, Michael Ackerman2, Cynthia S. Crowson3, Eric L. Matteson1 and Sherine E. Gabriel4, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Division of Cardiology, Mayo Clinic, Rochester Minnesota, Rochester, MN, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular morbidity and mortality. This risk persists even when RA disease characteristics are taken…
  • « Previous Page
  • 1
  • …
  • 2402
  • 2403
  • 2404
  • 2405
  • 2406
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology